- GLP-1 drugs such as Ozempic and Wegovy may reduce alcohol intake and other addictive behaviours as well as appetite.
- Researchers think the lateral septum, a brain region involved in reward and memory, may be central to this effect.
- This does not mean the drugs are addiction treatments yet, but it gives scientists a plausible biological route to investigate.
GLP-1 drugs were developed for type 2 diabetes and then transformed weight loss treatment.
Now they are raising another question.
Could the same drugs also help reduce addictive behaviours?
Human studies suggest GLP-1 agonists may reduce alcohol consumption.
Animal studies suggest they may also reduce use of cocaine, amphetamines, opiates and nicotine.
That has forced researchers to look again at how the brain links craving, reward and behaviour.
The obvious place to look would be the classic dopamine reward system.
This includes areas such as the ventral tegmental area and nucleus accumbens.
- GLP1 drugs commonly cause digestive side effects but may have wider benefits
- What happens when patients stop taking GLP-1 drugs
- Most weight lost on GLP-1 drugs returns within a year after stopping
These regions are heavily involved in pleasure, motivation and reinforcement.
But they do not appear to have many GLP-1 receptors, which makes them unlikely to be the whole explanation.
Attention is now shifting upstream to a brain region called the lateral septum.
This area has historically been linked to emotion, but newer research places it in a much more interesting role.
It receives information from the hippocampus, the brain region involved in memory, context and place.
The hippocampus helps answer “where am I?” and “when is this happening?”
The lateral septum seems to add another layer: “what is rewarding here?”
That matters for craving.
A person does not just want alcohol, food or nicotine in the abstract.
Craving is often tied to place, memory, routine and mental imagery.
The lateral septum may be one of the regions that links those pieces together.
It is also rich in GLP-1 receptors.
That makes it a strong candidate for explaining why GLP-1 drugs can reduce consumption.
- First GLP-1 pill for weight loss approved in the UK
- Ozempic breath: gum and mint sales may be getting a boost from GLP-1 users
- Experimental gut procedure may help stop weight regain after GLP-1 drugs
Recent animal studies show that activating GLP-1 receptors in the lateral septum can reduce food and alcohol intake.
This is still early neuroscience, not a ready-made treatment plan.
But it is an important shift.
The effect of GLP-1 drugs may not simply be about feeling full.
They may also quieten the mental pull of reward itself.
That could have major implications for obesity, alcohol dependence and other substance use disorders.
The hard part now is proving what applies to humans, who benefits and how to use these drugs safely outside their current indications.
